In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Initial experience with iMRI-DBS targeting of the subthalamic nucleus in Parkinson’s Disease

    Final Number:
    455

    Authors:
    Gregory Weiner MD; Samuel S. Shin MD PhD; Danielle M Wagner PA-C; Yeu-Fang Chang PhD; Robert Mark Richardson MD PhD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Recently, an interventional MRI (iMRI)-guided technique for implanting DBS electrodes based on target anatomy alone, without microelectrode recording (MER), was developed. Efficacy data reported by the center that originated this procedure is promising. We evaluated our initial experience with iMRI-guided bilateral subthalamic nucleus (STN) implantation as compared to concurrent MER-guided implantations.

    Methods: Thirty-nine consecutive patients undergoing bilateral subthalamic nucleus (STN) electrode placement for the treatment of Parkinson’s disease (PD), from August, 2012 to December, 2013, were studied. Patients underwent either iMRI-guided surgery using the ClearPoint system (iMRI-DBS), or MER-guided surgery using a Leksell frame (MER-DBS), a decision primarily based on patient preference. Radial errors in electrode placement were measured by comparing the initial AC-PC target coordinates to the lead artifact on postoperative MRI in the axial plane 4mm below the AC-PC line. Voltage thresholds for producing motor, sensory, gait, and associative side effects and thresholds for achieving benefits in rigidity, bradykinesia, tremor, and gait were tabulated from monopolar survey data obtained during initial programming one-month following lead implantation.

    Results: 19 (49%) and 20 (51%) patients underwent MER-DBS and iMRI-DBS , respectively. 37 electrodes were placed in each cohort. The mean OFF/ON motor UPDRS scores were 41/19 (MER) and 47/21 (iMRI). The mean radial error was 1.3 ± 0.7mm in the MER group vs. 1.0 ± 0.6mm in the MRI group (p=0.03). No clinically significant differences in side effect or symptom benefit thresholds obtained during initial programming were demonstrated.

    Conclusions: iMRI-DBS placement does not result in clinically significant differences in thresholds for production of either unwanted side effects or symptomatic benefit during initial programming, suggesting that electrode targeting does not suffer from lack of MER guidance. Follow up studies are necessary to determine whether short and long-term UPDRS motor scores are similarly equivalent.

    Patient Care: Supporting an alternative option for subthalamic nucleus stimulation in patient's with Parkinson's disease.

    Learning Objectives: To appreciate that short-term postoperative outcomes indicate equivalence between MER-guided DBS and iMRI-guided DBS for targeting the STN in Parkinson’s disease.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy